A Phase 1 interventional study of Mirikizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via pre-filled syringe compared to mirikizumab (reference) solution given via pre-filled syringe. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated.
Screening is required within 35 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 milliliter (mL) mirikizumab as 2 subcutaneous (SC) injections of 1 mL and 2 mL delivered via Pre-filled Syringe (PFS) to abdomen or arms or thighs on Day 1.
Drug: Mirikizumab
Participants received 3 mL citrate- free mirikizumab as 2 SC injections of 1 mL and 2 mL delivered via PFS to abdomen or arms or thighs on Day 1.
Drug: Mirikizumab
Administered SC.
Also known as: LY3074828
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation
PK: Cmax of Mirikizumab
Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation
PK: AUC\[0-∞\] of Mirikizumab
Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation
PK: AUC\[0-tlast\] of Mirikizumab
Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose
| Milestone | Mirikizumab - Abdomen | Mirikizumab - Arm | Mirikizumab - Thigh | Citrate-Free Mirikizumab - Abdomen | Citrate-Free Mirikizumab - Arm | Citrate-Free Mirikizumab - Thigh |
|---|---|---|---|---|---|---|
| Started | 74 | 76 | 76 | 75 | 75 | 74 |
| Received at least one dose of study drug | 74 | 76 | 76 | 75 | 75 | 74 |
| Completed | 72 | 74 | 75 | 75 | 74 | 74 |
| Not completed | 2 | 2 | 1 | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 |
PK: Cmax of Mirikizumab
| micrograms per milliliter (μg/mL) | Mirikizumab | Citrate-Free Mirikizumab |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation | 20.9 ± 43 | 20.9 ± 39 |
PK: AUC\[0-∞\] of Mirikizumab
| microgram*day per milliliter (μg*day/ mL | Mirikizumab | Citrate-Free Mirikizumab |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation | 331 ± 39 | 325 ± 36 |
PK: AUC\[0-tlast\] of Mirikizumab
| microgram*day per milliliter (μg*day/ mL | Mirikizumab | Citrate-Free Mirikizumab |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation | 327 ± 39 | 320 ± 36 |
Collected over Baseline Through Follow-Up (Up To 13 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mirikizumab - Abdomen | 0/74 (0%) | 0/74 (0%) | 27/74 (36.5%) |
| Mirikizumab - Arm | 0/76 (0%) | 0/76 (0%) | 38/76 (50%) |
| Mirikizumab - Thigh | 0/76 (0%) | 0/76 (0%) | 36/76 (47.4%) |
| Citrate-Free Mirikizumab - Abdomen | 0/75 (0%) | 0/75 (0%) | 11/75 (14.7%) |
| Citrate-Free Mirikizumab - Arm | 0/75 (0%) | 0/75 (0%) | 17/75 (22.7%) |
| Citrate-Free Mirikizumab - Thigh | 0/74 (0%) | 0/74 (0%) | 17/74 (23%) |
| Event | Mirikizumab - Abdomen | Mirikizumab - Arm | Mirikizumab - Thigh | Citrate-Free Mirikizumab - Abdomen | Citrate-Free Mirikizumab - Arm | Citrate-Free Mirikizumab - Thigh |
|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 19/74 | 31/76 | 31/76 | 6/75 | 12/75 | 12/74 |
| Medication errorInjury, poisoning and procedural complications | 6/74 | 6/76 | 5/76 | 5/75 | 5/75 | 4/74 |
| HeadacheNervous system disorders | 3/74 | 2/76 | 4/76 | 1/75 | 2/75 | 1/74 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Mirikizumab - Abdomen | Mirikizumab - Arm | Mirikizumab - Thigh | Citrate-Free Mirikizumab - Abdomen | Citrate-Free Mirikizumab - Arm | Citrate-Free Mirikizumab - Thigh | Total |
|---|---|---|---|---|---|---|---|
| Mean | 39.2 ± 12.9 | 41.9 ± 13.4 | 41.5 ± 11.9 | 40.3 ± 12.5 | 41.4 ± 12.5 | 40.8 ± 12.5 | 40.9 ± 12.6 |
| Sex: Female, Male(Participants) | Mirikizumab - Abdomen | Mirikizumab - Arm | Mirikizumab - Thigh | Citrate-Free Mirikizumab - Abdomen | Citrate-Free Mirikizumab - Arm | Citrate-Free Mirikizumab - Thigh | Total |
|---|---|---|---|---|---|---|---|
| Female | 38 | 50 | 41 | 36 | 38 | 35 | 238 |
| Male | 36 | 26 | 35 | 39 | 37 | 39 | 212 |
| Ethnicity (NIH/OMB)(Participants) | Mirikizumab - Abdomen | Mirikizumab - Arm | Mirikizumab - Thigh | Citrate-Free Mirikizumab - Abdomen | Citrate-Free Mirikizumab - Arm | Citrate-Free Mirikizumab - Thigh | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 42 | 48 | 48 | 45 | 44 | 44 | 271 |
| Not Hispanic or Latino | 32 | 27 | 28 | 30 | 31 | 30 | 178 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Mirikizumab - Abdomen | Mirikizumab - Arm | Mirikizumab - Thigh | Citrate-Free Mirikizumab - Abdomen | Citrate-Free Mirikizumab - Arm | Citrate-Free Mirikizumab - Thigh | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 0 | 0 | 2 | 4 |
| Asian | 2 | 1 | 0 | 0 | 3 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 13 | 8 | 12 | 9 | 12 | 13 | 67 |
| White | 56 | 62 | 62 | 64 | 56 | 53 | 353 |
| More than one race | 2 | 1 | 1 | 0 | 1 | 1 | 6 |
| Unknown or Not Reported | 1 | 2 | 1 | 2 | 3 | 1 | 10 |
| Region of Enrollment(Participants) | Mirikizumab - Abdomen | Mirikizumab - Arm | Mirikizumab - Thigh | Citrate-Free Mirikizumab - Abdomen | Citrate-Free Mirikizumab - Arm | Citrate-Free Mirikizumab - Thigh | Total |
|---|---|---|---|---|---|---|---|
| United States | 74 | 76 | 76 | 75 | 75 | 74 | 450 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2022 to primary completion in May 2023, 5 months.
Results were first posted in Mar 2025, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab